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Introduction
The use of particle beams such as carbon-ions and protons have several advantages over conventional X-or γ-ray beam radiotherapies, the most prominent of which is a lower radiation dose delivered to normal tissues surrounding the tumor [1] . Moreover, other potential advantages over the use of X-or γ-ray radiotherapies include a higher relative biological effectiveness (RBE) and a lower oxygen enhancement ratio [1, 2] . More than 50 centers currently use particle beams for radiotherapy with other centers under construction [1, [3] [4] [5] . Although particle beams have a relatively higher RBE and display less difference in sensitivity between the cell lines, compared with X-or γ-ray beams, the radiotherapeutic response of tumors post beamirradiation differed from the cell-lines or the tumor site [1, 6] . In clinical studies, tumor recurrences post-irradiation with particle beams have been also observed [1, 7] . Thus, an effective non-invasive means to evaluate the therapeutic efficacy of particle beam radiotherapies, as well as X-or γ-ray radiotherapy, early in the treatment protocol would be valuable.
Functional imaging with positron emission tomography (PET) using radiopharmaceuticals such as 2-[ [8, 9] . Thus, this imaging technique provides an earlier assessment of response to chemotherapy for cancer more than a structural or morphological diagnosis by X-ray computed tomography (CT) and magnetic resonance imaging (MRI) [10] [11] [12] . Since activated inflammatory immune cells are present and recruited at the irradiation sites post-irradiation and these cells also incorporated 18 F-FDG, which frequently occurs, this complicates diagnostic accuracy [13, 14] . 11 C-Met is, therefore, frequently used to estimate the therapeutic efficacy of particle beam radiotherapy [7, 12, 15] . However, due to the short half-life (20 min) of the 11 C-isotope, adjacency to GMP-capable cyclotron facilities is required to produce and use 11 C-Met for clinical practice [16] . Thus, the development of a longer half-life The uptake of 11 C-Met by tumor cells is multifaceted, as methionine is involved in many cellular functions such as a substrate for amino acid transporters (mainly via the L-type amino acid transporter 1 (LAT1) [17, 18] ), protein synthesis, and transmethylation [8, 19, 20] . Among these roles, it is the energy-dependent intracellular functions, such as protein synthesis and transmethylation, that are more reflective of the therapeutic effects of carbon-ion radiotherapy rather than the energy-independent amino acid transport System-L function that is involved in the transport of 11 C-Met [21] . Since a part of the intracellular metabolism of methionine is structurally methionine-specific (e.g. transmethylation), it is deemed difficult to develop longer lived radioisotope such as 18 F, 76 Br, and/or 123 I-labeled probes that reflect this particular energy-dependent aspect of the intracellular metabolism of 11 C-Met. Amino acids are transported into cells via the amino acid transport systems, which have been classified into 2 groups [20] . Transporters in the first group function in a sodium-independent manner, and contain the amino acid transport System-L. This energy-independent System-L transporter is involved in the transport of methionine into the cell. Transporters in the second group require a sodium chemical gradient and the membrane electric potential for their functional activity, and contain the amino acid transport System-A [20, 22, 23] . The driving force that energizes this type of transporter is maintained by Na + /K + ATPase. Thus, the System-A transporter is energy-dependent transporter while System-L is energy-independent transporter [24, 25] . And several 18 F-and 123 I-labeled labeled probes that are transported into cells via this amino acid transport System-A have been developed as a tumor-imaging agent [26] [27] [28] [29] [30] .
Since the energy-dependent intracellular metabolic processes that 11 C-Met is involved in are reflective of radiotherapeutic response [21] , we hypothesized whether the energy-dependent activity of the System-A transporter could be used to predict the radiotherapeutic efficacy of a carbon-ion beam at an early stage of the treatment process. The artificial amino acid, alpha-(methylamino)isobutyric acid (MeAIB), represents a standard substrate for all three system A subtypes; SNAT1, SNAT2, and SNAT4 [23, 31] , and is not metabolized within cells [27] . Thus, the accumulation of MeAIB in tumor cells may reflect the energy-dependent activity of System-A. In this context, we evaluated the activity of the energy-dependent amino acid transport System-A with 14 C-MeAIB in tumor cells post irradiation with a carbon-ion beam and assessed the potential of substrates for this energy-dependent System-A transporter to reflect the radiotherapeutic efficacy of the radiotherapy. As the short half-life of 11 C-labeled Met would preclude its suitability for these studies, 14 C-labeled analogue was used instead, in conjunction with the Heavy Ion Medical Accelerator in Chiba (HIMAC) synchrotron at National Institute of Radiological Sciences (NIRS) in Japan.
Materials and methods

General
Alpha-[1- C-Met, specific activity: 2.22 GBq/mmol) was purchased from GE Healthcare (Tokyo, Japan). Radioactivity counts were determined using a liquid scintillation counter (LSC-5100, Aloka, Tokyo). ATP was measured by a luminometer (TD-20/20, Turner Designs, CA). Fourweek-old male Balb/cAJcl-nu nude mice (Nihon Clea, Tokyo, Japan) were used in the in vivo studies. Other materials reagents were of reagent grade and used as received.
Irradiation
Carbon-ion beams were accelerated up to 290 MeV/u by HIMAC synchrotron at NIRS in Japan. Modulator films were used to achieve an LET value of 60 keV/μm within a 6-cm-wide spread-out-Bragg-peak (SOBP). All samples were irradiated at room temperature.
Cell culture
The human salivary gland (HSG) cell line [32] was generous gifts from NIRS. The HSG cell line has previously been used and described in preclinical radiobiologic experiments with the carbon-ion beams at NIRS [33, 34] . Moreover, the ridge filter in the instrument was designed so that the HSG cells were uniformly irradiated at the SOBP in the carbon-ion beam at NIRS [35] . Based on these prior experiments, the HSG cell line was used for these studies. The HSG cell was grown as a monolayer in Eagle's Minimum Essential Medium (EMEM, SigmaAldrich Japan, Tokyo), supplemented with 10% fetal bovine serum (SAFC Biosciences, Kansas) and 1% penicillin/streptomycin (10,000 units/mL, 10 mg/mL) at 37˚C in a 5% CO 2 atmosphere. Prior to the cell uptake experiments, HSG cells were washed twice with PBS and isolated as a single-cell suspension by trypsinizing with a solution of 0.25% trypsin in PBS. After the cells were resuspended in EMEM medium, cell numbers were counted using a Coulter counter (Beckman Coulter, Tokyo) and the cell concentration was adjusted to the desired concentration.
Cell uptake experiments
Cell uptake experiments were performed according to the procedure described by Samnick et al. [36] with slight modifications. The cell suspension was transferred to a 15-mL tube and then centrifuged for 5 min at 1,000 x g. The resulting supernatant was removed, and the pellet was washed with 2 mL of HEPES buffer (pH 7.4, 12 mM HEPES, 137 mM NaCl, 2.7 mM KCl, 1 mM MgCl 2 , and 5.6 mM D-glucose). To conduct the Na + -free uptake studies, NaCl was replaced with choline-Cl (Na + -free HEPES buffer). The cell suspension (500 μL) was transferred to 2-mL Eppendorf tubes at concentrations of 2 C-Met, 6.29 x 10 2 Bq, in HEPES buffer) with or without amino acid transport System-A or L inhibitors (5 mM MeAIB or 5 mM 2-amino-2-norbornane carboxylic acid (BCH), respectively) was added to the cells, which were then incubated at 37˚C or 4˚C for 5 min. The tracer uptake was stopped by the addition of 1 mL of ice-cold PBS and an additional 2 min in an ice bath, followed by centrifuging for 2 min at 1,000 x g. The resulting supernatant was removed, and the cell-pellet was washed three times with ice-cold PBS. Radioactivity was measured by first dissolution of the pellet in a tissue solubilizer (0.5 mL, SOLUENE-350, Perkin Elmer Japan), followed by the addition of a scintillator (5 mL, HYONIC-FLUOR, Perkin Elmer Japan) and counted on an automated liquid scintillation counter.
Cell uptake experiments after irradiation
Harvested and EMEM washed HSG tumor cells were counted using a Coulter counter and the cell concentration was adjusted to 1 x 10 6 cells or 2 x 10 6 cells that were plated in T-25 flasks.
These flasks were incubated at 37˚C in 5% CO 2 for 1 day. The cell bearing flasks were then irradiated with a carbon-ion beam to attain a dose of 3-Gy. Post-irradiation, the media in each flask was changed to fresh media, and flasks were incubated for the appropriate time for subsequent amino acid uptake studies conducted on the assigned day. On the study day, the cells were washed, harvested and counted using a Coulter counter to provide the surviving tumor cell number. The cell concentration then was adjusted to 2 x 10 6 /mL and the cell uptake of 14 C-MeAIB or 14 C-Met by HSG cells was investigated from 1-5 days post-irradiation using the procedure described above.
ATP content in cells after irradiation
Irradiated cells were prepared as described above. The cell suspension was transferred to a 15-mL tube and centrifuged at 1,000 x g for 5 min. The resulting supernatant was removed, and the pellet was washed twice with PBS and resuspended in PBS to a concentration of 3 x 10 5 cells/mL. A cellular ATP measurement kit for cells (Cosmo bio Ltd., Tokyo) was used to measure the ATP content of the cells, following the manufacturer's protocol. The content of ATP was measured using the chemiluminescence produced by the luciferase/luciferin reaction [37] .
In vivo experiments
HSG cells (1 x 10 6 cells) were transplanted subcutaneously to the left hind-limbs of nude mice 15 days prior to irradiation. Before irradiation, the tumor volumes were measured and conformed to 1.25 ± 0.18 cm 3 . After the tumors reached an appropriate size, under pentobarbital anesthesia (20 mg/kg) each mouse was immobilized on a Lucite plate and its left hind leg was placed in the irradiation field. In separate groups of mice, the implanted HSG tumors received a radiation dose of 6-Gy or 25-Gy from the carbon-ion beam. To investigate the uptake of 14 C-MeAIB or 14 C-Met at the irradiation site, the left hind leg (muscle) was also irradiated by the carbon-ion beam (25-Gy) as described above. The rate of tumor growth was assessed by daily measurements of tumor sizes from which estimates for tumor volume (v) were made using the formula v = a x b x c (where a, b, and c are tumor diameters). 14 C-MeAIB (11.1 kBq) or 14 C-Met (11.1 kBq) dissolved in saline was administrated intravenously before mice were sacrificed at 30 min. Tissues of interest were removed and weighed. The tissues were then solubilized in soluene-350 and Hionic-Fluor and radioactivity was measured using a liquid scintillation counter. Values were expressed as the mean (SD) for a group of 3-5 animals.
Statistical analysis
Results are expressed as the mean ± SD. Results were analyzed using the Tukey's multiplecomparison test (Graph Pad Prism, CA) to compare the significance of differences between two groups. Differences were considered significant when p values were less than 0.05.
Ethical approval
All animal studies were conducted in accordance with institutional ethical guidelines and were approved by the Chiba University Animal Care Committee. We regularly monitored each animal's health at every 2-3 days. If the tumor volumes in any animals were over 2.5 cm 3 , the individual animal was euthanized by decapitation. There are no mice that became ill or died at any time prior to the experimental endpoint. 
Results
Transport mechanisms of
C-Met in HSG cells
The tumor cell uptake of 14 C-Met was not reduced in Na + -free buffer or in the presence of MeAIB, a substrate of amino acid transport System-A. However, a significant reduction (13% of the control) was observed in the presence of BCH, a standard inhibitor of amino acid transport System-L (Fig 1) . On the other hand, the uptake of 14 C-MeAIB in Na + -free buffer was reduced to 11% of the control and was inhibited by MeAIB to 6% of the control, but was not affected by BCH (Fig 1) .
Cell numbers, tumor uptakes of 14 C-MeAIB and 14 
C-Met, and ATP contents in cells after irradiation
The time course of changes in the cell numbers after irradiation by the carbon-ion beam (3-Gy) is shown in Fig 2C. The cell growth was measured as cell numbers, and a slight increase was observed 1 day post-irradiation, which subsequently decreased with time, with a significant decrease in the cell population observed 5-days post-irradiation (p<0.05). In irradiated cells, the accumulation of 14 C-Met was reduced to 96%, 75%, and 24% of the controls at 1-, 3-, and 5-days post-irradiation, respectively, and was significantly reduced from day-3 onward (p<0.05) (Fig 2B) . Similarly, accumulation of 14 C-MeAIB by the irradiated cells was reduced to 98%, 83%, and 13% of the controls at 1-, 3-, and 5-days post-irradiation, respectively, and was also significantly reduced from day-3 onward (p<0.05) (Fig 2A) . The ATP content in all of these HSG cells was also measured post-irradiation (Fig 2D) , where no significant changes were observed over the 5-day post-irradiation period. the 6-Gy dose, tumor volume reductions were observed for up to 10 days post-irradiation, and were followed by a re-growth and significant volume increases (150% of the control by day 18). On the other hand, the irradiation of tumors with the 25-Gy dose resulted in an initial tumor volume increase 3 days post-irradiation, that was followed by a significant reduction in tumor size, with no tumor re-growth being detected up to 18 days post-irradiation.
Measurements of the in vivo tumor uptake of (Fig 5A; 60% from pre-irradiation) . Similarly, the in vivo tumor accumulation of 14 C-MeAIB was also significantly decreased 3-days post-irradiation with a 25-Gy dose (Fig 5B; 63% from pre-irradiation). When HSG tumor xenografts were irradiated with a lower dose (6-Gy), the tumor accumulation of 
Discussion
11
C-Met is a useful radiopharmaceutical to estimate the therapeutic efficiencies of radiotherapy such as conventional and particle radiotherapies [12, 15, 38, 39] . Indeed, 11 C-Met has been used to estimate the therapeutic efficacy of carbon-ion radiotherapy at NIRS. Among the cellular functions involved in 11 C-Met such as transport (System-L), protein synthesis, and transmethylation [8, [17] [18] [19] [20] , energy-dependent intracellular functions are more reflective of the therapeutic effects of carbon-ion radiotherapy [21] and conventional radiotherapy [40, 41] . Although a number of radiolabeled amino acid analogues using 18 F and 123 I have been developed and reported to display tumor uptake via this energy-independent transport System-L [20, 29, 42, 43] , these reagents have not been shown to provide information on subsequent intracellular energy-dependent processes similar to those observed with 11 C-Met, e.g. protein synthesis, and/or transmethylation, nor have they been evaluated in the radiotherapy studies at early stage of the treatment. It is with these considerations, herein, we evaluated whether the activity of the amino acid transport System-A (an energy-dependent transport system) may have a potential utility in estimating the radiotherapeutic effect at early stage of the treatment, analogues to those observed with 11 C-Met. The results of the in vitro cell uptake studies clearly showed that the cellular uptake of 14 C-MeAIB was significantly reduced under Na + -free conditions and was inhibited by MeAIB (>90%), but not by BCH (Fig 1) , indicating that 14 C-MeAIB was transported into HSG cells via an energy-dependent amino acid transport System-A. The uptake of 14 C-Met by HSG tumor cells was inhibited by BCH (>80%) (Fig 1) , but was not significantly affected by Na Fractionated irradiation is typically used during radiation treatment to improve the therapeutic ratio between target and normal tissue. Given the nature of the carbon-ion radiotherapy, the normal healthy cells surrounding the target area generally will receive a low dose of low-LET radiation and can escape from radiation-damage, while the LET of the therapeutic carbon-ion beams in target area remains effective [44] , thus the advantage gained by fractionation of a carbon-ion beam irradiation is significantly enhanced [36] . Considering this and because this study focused on the tumor responses post-irradiation of carbon-ion beam, single irradiations were used for both in vitro and in vivo studies.
The in vitro cell survival after 3-Gy of carbon-ion irradiation was reported earlier to be 5% and less than 0.01% at survival was observed at 6-Gy irradiation determined by a colony formation assay [6] . In addition to this, the observed pattern in the reduction in cell-numbers observed in vitro 5 days post 3-Gy irradiation (Fig 2C) , was similar to the reduction in tumor volume in vivo 5 days post 6-Gy irradiation (Fig 4) , hence a 3-Gy irradiation dose was chosen for the in vitro cellular responses studies. An examination of the effects of the carbon-ion beam (6-Gy or 25-Gy) on the tumor cell survival in an in vivo systems showed that no significant changes occurred in tumor volumes for up to 5 days post-irradiation. However, the sizes of tumors irradiated with the lower dose (6-Gy) displayed an increase by 10-day, while those of tumors irradiated with a higher dose (25-Gy) continued to decrease in volume. Under these conditions, 14 C-MeAIB, the energy-dependent System-A transporter was affected, while in the case of 14 C-Met, intracellular energy-dependent metabolic processes were disrupted, both of which result in displaying a decreased accumulation of the respective amino acid tracer at an early point in the treatment.
Most of the clinically established amino acid tracers such as I-VAIB and have also been developed [29, 30] , however, very few of these have been evaluated in human studies for monitoring the dose-response to radiotherapy. Our investigation and data suggested that the energy-dependent amino acid transport Systems-A may indeed be use as a target to evaluate radiolabeled amino acid substrates and to monitor the therapeutic efficacy of the particle beam radiotherapy at early stage of the treatment.
Conclusions
The results of the present study indicate that the activity of amino acid transport System-A reflects the therapeutic efficacy of particle radiotherapy at an early stage of the treatment, similar to that observed for the energy-dependent intracellular metabolism of 14 C-Met. Given these findings, several longer half-life 18 F-and 123 I-labeled probes developed for the energydependent amino acid transport System-A may also have a potential utility and be more practical (longer half-life, and more widely available) as imaging probes to evaluate the effect of particle beam radiotherapy for tumors at an early stage of the treatment regimen. 
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